Research Study

Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue
Principal Investigator 
Steven Schendel

Overview

Body Locations and Systems 
Glaucoma
ClinicalTrials.gov# 
NCT02419508
Status 
Recruiting
Study Start/End 
Mar 9, 2016 to Jan 24, 2018
Locations 
Vancouver Community
Name/Title 
Alexsandra Kuzmanovic, Research Coordinator
Phone 
604-875-4253
Purpose of Study 

The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a PGA in patients with open-angle glaucoma or ocular hypertension.

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.